Jefferies Financial Group Inc. Purchases New Shares in Abivax SA Sponsored ADR $ABVX

Jefferies Financial Group Inc. purchased a new position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 457,325 shares of the company’s stock, valued at approximately $38,827,000.

A number of other institutional investors have also added to or reduced their stakes in ABVX. Kennedy Capital Management LLC lifted its position in shares of Abivax by 7.1% during the 2nd quarter. Kennedy Capital Management LLC now owns 241,188 shares of the company’s stock worth $1,845,000 after buying an additional 15,997 shares in the last quarter. Federated Hermes Inc. bought a new position in shares of Abivax in the third quarter valued at approximately $8,448,000. Persistent Asset Partners Ltd bought a new position in shares of Abivax in the third quarter valued at approximately $815,000. Privium Fund Management B.V. purchased a new stake in shares of Abivax during the third quarter valued at approximately $2,582,000. Finally, Voya Investment Management LLC purchased a new stake in shares of Abivax during the third quarter valued at approximately $978,000. 47.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on ABVX. Morgan Stanley boosted their price objective on Abivax from $101.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Citizens Jmp raised their target price on Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research report on Tuesday, December 16th. Wedbush began coverage on Abivax in a research note on Tuesday, February 24th. They set an “outperform” rating and a $110.00 target price on the stock. BTIG Research reissued a “buy” rating and issued a $150.00 price target on shares of Abivax in a report on Wednesday, February 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $134.75.

Abivax Price Performance

Abivax stock opened at $109.33 on Monday. The business’s 50 day simple moving average is $121.24 and its 200 day simple moving average is $107.82. Abivax SA Sponsored ADR has a 12 month low of $4.77 and a 12 month high of $148.83. The company has a market cap of $8.65 billion, a price-to-earnings ratio of -26.16 and a beta of 1.00. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03.

Abivax (NASDAQ:ABVX) last released its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The business had revenue of ($4.92) million during the quarter. Sell-side analysts forecast that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.